(Bloomberg) London remains Europe’s top venue for sales of shares in listed companies, as a recent raft of secondary deals eclipses a lack of UK initial public offerings.Most Read from BloombergIran State TV Says ‘No Sign of Life’ at Helicopter Crash SiteSpeedier Wall Street Trades Are Putting Global Finance On EdgeEbrahim Raisi, Iranian President Confronting West, Dies at 63Saudi Crown Prince Postpones Japan Trip Over King’s HealthChina’s Housing Rescue Too Small to End Crisis, Analysts SayT
Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
UBS reiterates its neutral stance on Sartorius Stedim Biotech, with a price target reduced from €276 to €232. This new target implies a potential upside of 11% for the stock of the French.